Stay updated with breaking news from Quality Considerations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has announced the availability of a guidance for industry entitled ‘‘Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.’’
Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and...
The FDA announced new guidance entitled Cannabis and Cannabis-Derived Compounds; Quality Considerations for Clinical Research. Those involved in the clinical research of cannabis can rely on this FDA guidance for recommended sources of cannabis for clinical research and resources.
FDA issued its final guidance, Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research. The agency outlines current recommendations for drug sponsors developing cannabis and cannabis-derived compounds for use in human drug clinical research.
On January 23, 2023, the U.S. Food and Drug Administration (FDA) issued its final guidance, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research” (the...